Aspire Biopharma, Inc. (NASDAQ:PWUP)

PRESS RELEASE

published on 06/10/2025 at 14:30, 1 year 1 month ago

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer
Michael Howe to become CEO of Aspire Biopharma Holdings, Inc. on June 10, 2025. His extensive career in leading brands and early-stage companies makes him a strategic fit for the role

Healthcare Board Member CEO Michael Howe Aspire Biopharma Holdings, Inc.
BRIEF

published on 05/28/2025 at 14:35, 1 year 1 month ago

Aspire Biopharma dévoile BUZZ BOMB™ : une nouvelle ère dans les compléments pré-entraînement

Technologie Sublinguale Marché Du Fitness Supplément Pré-entraînement BUZZ BOMB™ Livraison De Caféine
BRIEF

published on 05/28/2025 at 14:35, 1 year 1 month ago

Aspire Biopharma Unveils BUZZ BOMB™: A New Era in Pre-Workout Supplements

Sublingual Technology Fitness Market Pre-workout Supplement BUZZ BOMB™ Caffeine Delivery
PRESS RELEASE

published on 05/28/2025 at 14:30, 1 year 1 month ago

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025
Aspire Biopharma introduces BUZZ BOMB™, a sublingual pre-workout supplement delivering rapid caffeine to support athletes' performance. Six flavors available in convenient single servings. Global pre-workout supplements market on the rise

Aspire Biopharma Pre-workout Supplement Sublingual BUZZ BOMB™ Caffeine
BRIEF

published on 05/20/2025 at 14:35, 1 year 1 month ago

Aspire Biopharma lance un essai de phase 1 sur une formulation d'aspirine à haute dose

Développement Clinique Examen De La FDA Essai De Phase 1 Aspirine À Haute Dose Absorption Sublinguale
BRIEF

published on 05/20/2025 at 14:35, 1 year 1 month ago

Aspire Biopharma Begins Phase 1 Trial of High-Dose Aspirin Formulation

Clinical Development Phase 1 Trial FDA Review High-dose Aspirin Sublingual Absorption
PRESS RELEASE

published on 05/20/2025 at 14:30, 1 year 1 month ago

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Aspire Biopharma initiates Phase 1 trial for high-dose aspirin formulation in the United States, targeting accelerated approval with positive data anticipated in 3Q 2025

Accelerated Approval Phase 1 Trial FDA Feedback Aspire Biopharma High-dose Aspirin Formulation
BRIEF

published on 05/08/2025 at 14:05, 1 year 2 months ago

Aspire Biopharma to Participate in Sidoti Virtual Investor Conference

Investor Presentation Drug Delivery Technology Sidoti Conference Aspire Biopharma Virtual Meetings
BRIEF

published on 05/08/2025 at 14:05, 1 year 2 months ago

Aspire Biopharma participera à la conférence virtuelle des investisseurs de Sidoti

Presentation Aux Investisseurs Technologie D'administration De Médicaments Conférence De Sidoti Aspire Biopharma Réunions Virtuelles
PRESS RELEASE

published on 05/08/2025 at 14:00, 1 year 2 months ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21
Aspire Biopharma to present at Sidoti Virtual Investor Conference on May 21 and host virtual one-on-ones with investors. Company's disruptive drug delivery technology highlighted

Sidoti Virtual Investor Conference Virtual Presentation One-on-one Meetings Drug Delivery Technology Aspire Biopharma

Published on 07/14/2026 at 01:45, 4 hours 22 minutes ago

Arctic Fox Lithium Approved for Trading on the OTCQB Venture Market and Announces DTC Eligibility
Published on 07/14/2026 at 00:01, 6 hours 6 minutes ago

Captor Capital Announces Delay in its Annual Filings
Published on 07/13/2026 at 23:10, 6 hours 57 minutes ago

Galaxy Ventures Inc. Announces Director Resignation
Published on 07/13/2026 at 21:35, 8 hours 32 minutes ago

ATHA Energy Announces Corporate Activities Update
Published on 07/13/2026 at 20:00, 10 hours 7 minutes ago

IBC Announces Share-Based Compensation to Directors

View all ACCESSWIRE

Published on 07/14/2026 at 04:45, 1 hour 22 minutes ago

Asia’s Debut of LEAP East in HKCEC Marks Hong Kong’s Largest Inaugural Tech Summit
Published on 07/13/2026 at 22:30, 7 hours 37 minutes ago

Half-year 2026 Results Media and Investor Conference Call and Webcast
Published on 07/13/2026 at 21:20, 8 hours 47 minutes ago

Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Published on 07/13/2026 at 21:17, 8 hours 49 minutes ago

EQS-Adhoc: Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Published on 07/13/2026 at 20:48, 9 hours 19 minutes ago

EQS-Adhoc: Gateway Real Estate AG: Forecast for the financial year 2026

View all EQS

Published on 07/13/2026 at 18:00, 12 hours 7 minutes ago

CP Icade - Icade reprend 100% de la propriété de la Tour Eqho à la Défense
Published on 07/13/2026 at 18:00, 12 hours 7 minutes ago

PR Icade - Icade regains full ownership of the Eqho Tower in La Défense
Published on 07/13/2026 at 18:00, 12 hours 7 minutes ago

THERMADOR GROUPE : 2026 half-year turnover
Published on 07/13/2026 at 18:00, 12 hours 7 minutes ago

THERMADOR GROUPE : publication du chiffre d'affaires semestriel 2026
Published on 07/13/2026 at 17:45, 12 hours 22 minutes ago

Weekly share buyback

View all LES ECHOS COMFI WIRE

News